" "
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Diagnosis of Parvovirus B19 in Pregnancy Enhanced

Published: Monday, July 29, 2013
Last Updated: Monday, July 29, 2013
Bookmark and Share
The Iam Parvo assay is a rapid quantitative molecular assay that expands DiaSorin's diagnostic portfolio for this potentially life-threatening virus.

Parvovirus B19 (B19V) is a common childhood infection.  It causes particular concern where a pregnant woman has had contact with a B19V infected individual, or where maternal B19V infection is suspected.    During pregnancy, from as early as 6 weeks gestation, B19V can transfer from mother to foetus across the placenta. Such infection may cause hydrops fetalis, miscarriage or poor outcomes (including severe neurological disease) in surviving babies.1

Diagnosis of maternal infection relies on the detection of IgM and IgG antibodies. The presence of IgG antibodies to B19V indicates a previous infection, but it is estimated that approximately 25 to 45% of women of childbearing age do not possess these antibodies and are therefore susceptible to infection.2 

First line serology testing will indicate current active B19V infection.  However, when serological test results are negative but infection is still suspected, clinicians can rapidly confirm diagnosis using the new, highly sensitive, Iam Parvo molecular assay.  This confirmation is particularly important in the 8 - 12 week period after maternal infection, when the sensitivity of IgM antibody detection varies from 63% to 70% and serological testing alone may not give the full picture.4  Rapid diagnosis of infection allows the foetus to be monitored and appropriate care referrals to be made.

“Iam Parvo is a molecular assay that, when used together with serological testing, enhances the clinical management of B19V-complicated pregnancies,” said Paul Eros, Global Vice President Molecular, DiaSorin. “With this molecular assay launch we underpin DiaSorin’s leadership in Parvovirus B19 testing and demonstrate our commitment to providing a complete diagnostic solution for this important infectious disease. Iam Parvo is the latest addition to the unique and rapidly expanding DiaSorin Q-LAMP assay portfolio for our Liaison® Iam molecular instrument, a benchtop device which meets the needs of laboratories by providing them with a cost-effective, scaleable, molecular diagnostic solution.” 

Calibrated against the WHO standard for B19V, Iam Parvo provides exceptional time-to-result benefits when compared to PCR, with equivalent specificity.  The Liaison Iam instrument uses DiaSorin’s proprietary Q-LAMP technology.

“People should not confuse DiaSorin Q-LAMP with conventional LAMP technology”, continues Eros, “DiaSorin Q-LAMP assays provide many advantages.  They are rapid, real-time, fluorescent, quantitative/qualitative assays designed to be used for multiplexed applications, enabling amplification and detection of multiple targets in a single reaction”.    

The Iam Parvo assay is CE-IVD validated for use outside of the USA and Canada only.

For more information about the Iam Parvo assay and the Liaison Iam molecular instrument email info@ie.diasorin.com or visit www.diasorin.com

 1.    Dijkmans A.C. et al. Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications. Curr. Opin. Obstet. Gynecol. (2012) 24:95-101. 

2.    Rohrer C., Gartner B., Sauerbrei A. et al. Seroprevalence of Parvovirus B19 in the German population.  Epidemiol. Infect. (2008), 36:1-7

3.    Bredl S., Plentz A., Wenzel J.J. et al. False negative serology in patients with acute Parvovirus B19 infection. J. Clin. Viro. (2011) 51:115-120 

4.    Enders M., Helbig S, Hunjet A. et al. Comparative evaluation of two commercial enzyme immunoassays for serodiagnosis of gestational Parvovirus B19 infection. J. Virol. Methods (2007) 146:409-413).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!